Sangamo THERAPEUTICS, Inc. (SGMO) intrinsic value & 10-year financials
Sangamo THERAPEUTICS, Inc. (SGMO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 8.2% a year to $39.6M, with an average return on invested capital of 722.6%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $39.6M
- Revenue growth (10-yr CAGR)
- 8.2%
- ROIC (10-yr avg)
- 722.6%
- Free cash flow (FY2025)
- -$97.3M
SGMO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $39.6M | -$122.9M | -$0.44 | -$97.3M | -306.5% | 7997.4% |
| FY2024 | $57.8M | -$97.9M | -$0.49 | -$67.4M | -179.9% | -265.1% |
| FY2023 | $176.2M | -$257.8M | -$1.48 | -$246.0M | -155.5% | -176.4% |
| FY2022 | $111.3M | -$192.3M | -$1.25 | -$243.8M | -180.8% | -84.9% |
| FY2021 | $110.7M | -$178.3M | -$1.23 | -$256.5M | -165.6% | -56.8% |
| FY2020 | $118.2M | -$121.0M | -$0.90 | $155.2M | -109.6% | -32.4% |
| FY2019 | $102.4M | -$95.2M | -$0.85 | -$165.1M | -102.7% | -34.0% |
| FY2018 | $84.5M | -$68.3M | — | -$5.9M | -91.4% | -34.1% |
| FY2017 | $36.6M | -$54.6M | — | $7.4M | -154.1% | -34.8% |
| FY2016 | $19.4M | -$71.7M | — | -$66.6M | -374.2% | -53.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
SANGAMO THERAPEUTICS, INC is a consistent compounder, expanding top-line revenue at 8.2% annually over the past decade.
SANGAMO THERAPEUTICS, INC has historically struggled to out-earn its cost of capital, averaging just -25.5% ROIC.
SANGAMO THERAPEUTICS, INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, SANGAMO THERAPEUTICS, INC is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-9.30 per share.